

I'm not a bot









## ajcc 8th stage إرشادات سرطان الجلد الصادرة عن

Display options Format AbstractPubMedPMID The eighth edition of the American Joint Committee on Cancer (AJCC) melanoma staging system was implemented in the United States on 1 January 2018. Areas covered: This article provides an overview of important changes in the eighth edition AJCC staging system from the seventh edition based on analyses of a large international melanoma database. The clinical implications of these changes for melanoma treatment are also discussed. Expert commentary: A standardized and contemporary cancer staging system that facilitates accurate risk stratification is essential to guide patient treatment. The eighth edition of the AJCC staging system is currently the most widely accepted approach to melanoma staging and classification at initial diagnosis. Keywords: AJCC; American Joint Committee on Cancer; Melanoma; TNM; eighth edition; prognosis; staging. Declaration of interest: JE Gershenwald has served on advisory boards for Merck, Syndax, and Castle Biosciences, unrelated to the content of this article. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Figure 1. Comparison of AJCC seventh edition... Figure 1. Comparison of AJCC seventh edition and AJCC eighth edition staging systems: melanoma-specific survival... Figure 1. Comparison of AJCC seventh edition and AJCC eighth edition staging systems: melanoma-specific survival of patients with stage I and II melanoma by T subcategory. All patients with T1N0 melanoma were included. Patients with T2 to T4 melanoma were included only if they had negative sentinel lymph nodes. aWith permission from Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017; 67:472–491.bWith permission from Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–6206. Figure 2. Melanoma-specific survival by (A, B)... Figure 2. Melanoma-specific survival by (A, B) N categories and (C) presence or absence of... Figure 2. Melanoma-specific survival by (A, B) N categories and (C) presence or absence of microsatellites, satellites, and/or in-transit metastases. With permission from Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017; 67:472–491. Figure 3. Comparison of AJCC seventh edition... Figure 3. Comparison of AJCC seventh edition and AJCC eighth edition staging systems: melanoma-specific survival... Figure 3. Comparison of AJCC seventh edition and AJCC eighth edition staging systems: melanoma-specific survival of patients by stage I and II subgroups. aWith permission from Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017; 67:472–491.bWith permission from Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–6206. Figure 4. Comparison of AJCC seventh edition... Figure 4. Comparison of AJCC seventh edition and AJCC eighth edition staging systems: melanoma-specific survival... Figure 4. Comparison of AJCC seventh edition and AJCC eighth edition staging systems: melanoma-specific survival of patients by stage III subgroups. aWith permission from Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017; 67:472–491.bWith permission from Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–6206. Figure 5. AJCC eighth edition pathological prognostic... Figure 5. AJCC eighth edition pathological prognostic groups (TNM) for stage I to IV cutaneous... Figure 5. AJCC eighth edition pathological prognostic groups (TNM) for stage I to IV cutaneous melanoma. T0 – no evidence of primary tumor (e.g. unknown primary or completely regressed melanoma); Tis – melanoma in situ; TX – thickness cannot be assessed; NX – Regional nodes not assessed (e.g. SLN biopsy not performed, regional nodes previously removed for another reason). Exception: pathological N category is not required for T1 melanoma, use cN. \*Pathological stage is IV for Any T, any N and M1 disease. aAdapted and used with permission from Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017; 67:472–491. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, Flaherty KT, Balch CM, Thompson JF, for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform. Gershenwald JE, et al. CA Cancer J Clin. 2017 Nov;67(6):472-492. doi: 10.3322/caac.21409. Epub 2017 Oct 13. CA Cancer J Clin. 2017. PMID: 29028110 Free PMC article. Classification of 3097 patients from the Japanese melanoma study database using the American joint committee on cancer eighth edition cancer staging system. Fujisawa Y, Yoshikawa S, Minagawa A, Takenouchi T, Yokota K, Uchi H, Noma N, Nakamura Y, Asai J, Kato J, Fujiwara S, Fukushima S, Uehara J, Hoashi T, Kaji T, Fujimura T, Namikawa K, Yoshioka M, Murata N, Ogata D, Matsuyama K, Hatta N, Shibayama Y, Fujiyama T, Ishikawa M, Yamada D, Kishi A, Nakamura Y, Shimauchi T, Fujii K, Fujimoto M, Itoh H, Katoh N, Fujisawa Y, et al. J Dermatol Sci. 2019 May;94(2):284-289. doi: 10.1016/j.jdermsci.2019.04.003. Epub 2019 Apr 17. J Dermatol Sci. 2019. PMID: 31023613 Staging and prognosis of cutaneous melanoma. Dickson PV, Gershenwald JE, Dickson PV, et al. Surg Oncol Clin N Am. 2011 Jan;20(1):1-17. doi: 10.1016/j.soc.2010.09.007. Surg Oncol Clin N Am. 2011. PMID: 21111956 Free PMC article. Review. Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors. Waninger JJ, Ma VT, Journey S, Skvarce J, Chopra Z, Tezel A, Bryant AK, Mayo C, Sun Y, Sankar K, Ramnath N, Lao C, Sussman JB, Fecher L, Alva A, Green MD, Waninger JJ, et al. JAMA Netw Open. 2021 Mar 1;4(3):e210980. doi: 10.1001/jamanetworkopen.2021.0980. JAMA Netw Open. 2021. PMID: 33687443 Free PMC article. Staging Melanoma: What's Old and New. Ramalingam K, Allamaneni SS, Ramalingam K, et al. Surg Clin North Am. 2020 Feb;100(1):29-41. doi: 10.1016/j.suc.2019.09.007. Epub 2019 Oct 29. Surg Clin North Am. 2020. PMID: 31753114 Review. Development of a prognostic model for patients with nodular melanoma of the lower extremities: a study based on the SEER database. Zhang S, Tian S, Qin X, Mou H, He B, Wang Y, Xue B, Lin W, Zhang S, et al. Arch Dermatol Res. 2024 Aug 23;316(8):563. doi: 10.1007/s00403-024-03282-9. Arch Dermatol Res. 2024. PMID: 39177925 Adjuvant Therapy for High-Risk Stage II Melanoma: Current Paradigms in Management and Future Directions. Vargas GM, Farooq MS, Karakousis GC, Vargas GM, et al. Cancers (Basel). 2024 Jul 29;16(15):2690. doi: 10.3390/cancers16152690. Cancers (Basel). 2024. PMID: 39123418 Free PMC article. Review. Treatment Patterns and Outcomes of Stage III Melanoma Patients with Positive Sentinel Lymph Node Biopsy: A Real-Life Experience. Rocuzzo G, Macagno N, Grignani P, Astrua C, Brizio MC, Cavaliere G, Picciotto F, Caliendo V, Fruttero E, Ribero S, Fava P, Quaglino P, Rocuzzo G, et al. J Clin Med. 2024 Sep 4;13(17):5238. doi: 10.3390/jcm13175238. J Clin Med. 2024. PMID: 39274453 Free PMC article. Long-term survival of stage IV melanoma patients: evaluation on 640 melanoma patients entering stage IV between 2014 and 2017. Reitmajer M, Leiter U, Nanz L, Amaral T, Flatz L, Garbe C, Forschner A, Reitmajer M, et al. J Cancer Res Clin Oncol. 2024 Jan 18;150(1):15. doi: 10.1007/s00432-023-05533-0. J Cancer Res Clin Oncol. 2024. PMID: 38238578 Free PMC article. Development of Personalized Surgical Strategies for Precisely Battling Malignant Melanoma. Isaak AJ, Clements GR, Buenaventura RGM, Merlino G, Yu Y, Isaak AJ, et al. Int J Mol Sci. 2024 May 4;25(9):5023. doi: 10.3390/jms25095023. Int J Mol Sci. 2024. PMID: 38732242 Free PMC article. Review. See all "Cited by" articles Emily Y. Keung, MD Clinical Fellow Complex General Surgical Oncology Department of Surgical Oncology University of Texas MD Anderson Cancer Center Houston, TX Charles M. Balch, MD Professor, Department of Surgical Oncology University of Texas MD Anderson Cancer Center Houston, TX Jeffrey E. Gershenwald, MD Professor, Department of Surgical Oncology Medical Director, Melanoma and Skin Center University of Texas MD Anderson Cancer Center Houston, TX Allan C. Halpern, MD Chief, Dermatology Service Memorial Sloan Kettering Cancer Center New York, NY Download as PDF The seventh edition of the American Joint Committee on Cancer (AJCC) staging system for cutaneous melanoma was implemented in 2010 following its introduction in 2009.1,2 In 2016, the Melanoma Expert Panel revised and published the eighth edition of the AJCC melanoma staging system, which was formally implemented nationwide January 1, 2018. Based on analyses of a large international melanoma database, key changes have been made in the new system to improve staging and prognostication, risk stratification and selection of patients for clinical trials. With the ever-growing list of increasingly effective treatments available today, it is more important than ever to stage patients accurately so that the monotherapies and combination therapies approved across different stage levels can be used most effectively, and patients can be optimally informed about their options and considered for the most promising and appropriate clinical trials. Here, we have distilled the most important changes in the new AJCC melanoma staging system, adapting them from the chapter on cutaneous melanoma in the eighth edition and the recently published analyses of the international database by the Melanoma Expert Panel.3,4 Determinants of Primary Tumor (T) Status Primary melanoma thickness and ulceration continue to define T category strata, but tumor thickness is to be measured to the nearest 0.1 mm, not the nearest 0.01 mm. The definitions of T1a and T1b have been revised so that T1a melanomas include those